Form 4: XOMA Royalty Corp Director Granted Restricted Stock Units

Natasha Hernday, a Director at XOMA Royalty Corp, was granted 5,971 restricted stock units (RSUs) on May 21, 2025, as part of her compensation.

Summary

• Natasha Hernday, a Director of XOMA Royalty Corp (XOMA), received a grant of 5,971 restricted stock units (RSUs) on May 21, 2025.
• Each RSU represents the right to receive one share of common stock of the Company upon settlement.
• The RSUs were granted at a price of $0, which is typical for equity compensation grants.
• These RSUs will vest on the first anniversary of the grant date, contingent upon Ms. Hernday's continued service to the Company.
• Following this transaction, Natasha Hernday beneficially owns a total of 9,006 shares of common stock, including these newly granted RSUs.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as the RSU grant aligns director interests with shareholders, which is generally viewed favorably for corporate governance and long-term value creation. It is a routine compensation event.

Positives

• The grant of restricted stock units to a director aligns the interests of the director with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• Equity compensation is a standard practice for attracting and retaining qualified board members in publicly traded companies.

Future Outlook

The granted restricted stock units are scheduled to vest on the first anniversary of the grant date, subject to the director's continued service, indicating a future equity issuance.

Management Comments

• The grant of 5,971 restricted stock units to Director Natasha Hernday reflects the company's compensation strategy for its board members, aiming to align their long-term interests with shareholder value.

Industry Context

The grant of restricted stock units is a common form of equity compensation for directors and executives across various industries, including the biotechnology and royalty sectors, used to incentivize long-term commitment and performance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of director compensation is a widely accepted practice across public companies, including those in the biotechnology and pharmaceutical royalty sectors, such as Royalty Pharma plc or Ligand Pharmaceuticals Incorporated, which also utilize equity-based incentives to align management and board interests with shareholder returns.
• The vesting schedule tied to continued service is a standard mechanism to ensure retention and ongoing commitment from board members, consistent with corporate governance best practices.

Corporate Governance

Related Party Transactions

• The grant of 5,971 restricted stock units to Natasha Hernday, a Director of XOMA Royalty Corp, constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of RSUs may result in minor future dilution upon vesting but is intended to align the director's interests with long-term shareholder value.
• Employees: While not directly impacting general employees, this type of compensation structure for directors sets a precedent for equity-based incentives within the company's overall compensation philosophy.

Next Steps

• The 5,971 restricted stock units granted to Natasha Hernday are expected to vest on May 21, 2026, subject to her continued service to XOMA Royalty Corp.

Key Dates

Keywords

XOMA Royalty Corp, XOMA, Restricted Stock Units, RSU, Director Compensation, Equity Grant, SEC Form 4, Insider Transaction, Corporate Governance, Biotechnology, Royalty Company